Serum values of tumour necrosis factor‐&agr; and of soluble tumour necrosis factor‐R55 in melanoma patients

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Melanoma research

• Publication date

  2000-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00008390-200006000-00007PMID 10890379
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.

  1998cited by this paper
• Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients.

  1998cited by this paper
• Multifaceted inhibition of anti‐tumour imm_une mechanisms by soluble tumour necrosis factor receptor type I

  1998cited by this paper
• Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.

  1998cited by this paper
• Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.

  1997cited by this paper
• Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer.

  1996cited by this paper
• Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in endometrial cancer.

  1996cited by this paper
• Tumour necrosis factor (TNF) soluble receptors in malignant melanoma: correlation with soluble ICAM-1 levels.

  1996cited by this paper
• Pattern of soluble TNF receptors I and II in sepsis

  1995cited by this paper
• Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis

  1995cited by this paper
• Two tumour necrosis factor receptors: structure and function.

  1995cited by this paper
• Leukemic cells in hairy cell leukemia and B cell chronic lymphocytic leukemia release soluble TNF receptors.

  1995cited by this paper
• Serum levels of tumour necrosis factor-alpha in patients with B-cell chronic lymphocytic leukaemia.

  1994cited by this paper
• Slow release of soluble TNF receptors by monocytes in vitro.

  1994cited by this paper
• Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy

  1993cited by this paper
• Two TNF receptors.

  1992cited by this paper
• High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia.

  1992cited by this paper
• Cytokines and HIV infection: is AIDS a tumor necrosis factor disease?

  1991cited by this paper
• Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients.

  1991cited by this paper
• Isolation and characterization of a tumor necrosis factor binding protein from urine

  1989cited by this paper
• The biology of cachectin/TNF--a primary mediator of the host response.

  1989cited by this paper

• Saffron anti-metastatic properties, ancient spice novel application

  2021cites this paper
• Dietary crocin reverses melanoma metastasis

  2018cites this paper
• Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity.

  2017cites this paper
• –308 G/A TNF-α gene polymorphism influences the course of basal cell carcinoma in a Polish population

  2015cites this paper
• THE ASSOCIATION BETWEEN THE IL-1 PATHWAY

  2014cites this paper
• Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma: An Overview

  2012cites this paper
• Melanoma progression, gene expression and DNA microarrays.

  2009cites this paper
• The new melanoma: a novel model for disease progression

  2008cites this paper
• Simultaneous analysis of circulating human cytokines using a high-sensitivity cytokine biochip array.

  2008cites this paper
• MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF‐β and pro‐inflammatory cytokines

  2005cites this paper
• Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro

  2005cites this paper
• The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma

  2005cites this paper
• Serum Levels of Tumor Necrosis Factor Alpha Correlate with Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

  2004cites this paper
• Prognostic significance of tumor necrosis factor receptor in colorectal adenocarcinoma.

  2003cites this paper
• Potential of p38 MAP kinase inhibitors in the treatment of cancer.

  2003cites this paper
• Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.

  2002cites this paper
• Construction of an expression cassette with hTNF-alpha gene for transient expression of the gene in mammalian cells.

  2001cites this paper